EuroPCR 2023 | iFR vs FFR Guided Revascularization in Left Main De Novo Lesions

Acute coronary syndrome guidelines recommend the use of iFR and FFR guided invasive management for patients with high risk ischemia regardless medical treatment. However, iFR and FFR they are often considered exchangeable.  Prior literature has shown there can be a discrepancy of around 20% between these techniques when it comes to revascularization outcomes.  Choosing the<a href="https://solaci.org/en/2023/05/17/europcr-2023-ifr-vs-ffr-guided-revascularization-in-left-main-de-novo-lesions/" title="Read more" >...</a>

ATC sobre arterias nativas o puentes venosos, ¿cuál tiene mejor pronóstico?

Real-World Revascularization Strategy for Left Main Coronary Artery: Surgery or PCI?

There are many current randomized trials comparing percutaneous coronary intervention (PCI) with myocardial revascularization surgery (MRS) for the treatment of left main coronary artery disease (LMCAD). In the European Society of Cardiology guidelines, PCI is classified as Ia (LMCAD with low-complexity coronary disease) or IIa indication (intermediate complexity), whereas, according to the American Heart Association<a href="https://solaci.org/en/2023/01/11/real-world-revascularization-strategy-for-left-main-coronary-artery-surgery-or-pci/" title="Read more" >...</a>

Claudicación Intermitente: ¿el tratamiento invasivo es superior al tratamiento farmacológico?

Long-Term Mortality in Non-Obstructive Lesions in the Left Main Coronary Artery

Left main coronary artery (LMCA) intervention with significant lesions on both coronary angiography and intravascular ultrasound (IVUS), either through angioplasty (PCI) or myocardial revascularization surgery (MRS), is directly related to a decrease in long-term adverse clinical events. However, the relationship between subclinical LMCA disease (preserved luminal diameters) and long-term mortality is still unknown. A retrospective<a href="https://solaci.org/en/2022/11/24/long-term-mortality-in-non-obstructive-lesions-in-the-left-main-coronary-artery/" title="Read more" >...</a>

SOLACI-SOCIME 2022 - Distal Left Main Coronary Artery

Complex PCI: Distal Left Main Coronary Artery – SOLACI-SOCIME 2022

✔️ Complex PCI: Distal Left Main Coronary Artery – SOLACI-SOCIME 2022. ✔️ SOLACI-SOCIME 2022 Scientific Session.  👨‍🏫 Contents: 00:13 – Welcoming words – Dr. Álvaro Contreras (MEX) 01:18 – LM-PCI: IVUS and FFR/IFR? – Dr. Hector García-García (USA) 17:06 – DK Crush or provisional stenting? – Dr. Carlos Uribe (COL) 32:22 – Optimal antiplatelet anti<a href="https://solaci.org/en/2022/09/20/complex-pci-distal-left-main-coronary-artery-solaci-socime-2022-2/" title="Read more" >...</a>

Bifurcación de tronco de coronaria distal: cantidad de stents

Provisional vs Dual Stenting in Left Main: An Endless Discussion?

True left main stem bifurcation patients have shown fewer adverse events with stepwise provisional stenting vs systematic dual stenting as first strategy, even though the difference was not significant. Usually, for any other vessel, the preferred technique is provisional stenting. However, when it comes to the left main, there is a randomized, dedicated, well designed<a href="https://solaci.org/en/2021/11/30/provisional-vs-dual-stenting-in-left-main-an-endless-discussion/" title="Read more" >...</a>

AHA 2021 | Meta-análisis de cirugía vs angioplastia para el tronco de la coronaria izquierda

AHA 2021 | Meta-Analysis of Surgery vs. Angioplasty in Left Main Coronary Artery Disease

According to this new meta-analysis (presented at AHA 2021 and published in The Lancet), mortality is similar between surgery and angioplasty to treat left main coronary artery in patients with simple or intermediate anatomy. This new study estimates that, after 5 years, mortality with surgery would be 11.2% vs. 10.2% with angioplasty, a non-significant difference. This debate<a href="https://solaci.org/en/2021/11/25/aha-2021-meta-analysis-of-surgery-vs-angioplasty-in-left-main-coronary-artery-disease/" title="Read more" >...</a>

IVUS vs OCT para guiar la angioplastia ¿Cuál elegir?

IVUS vs iFR for Left Main Decision Making

No decision on the coronary tree has more impact than left main intervention. This makes interventionists prone to over and underestimation of angiographic imaging. In other words, in real life we never report on angiograms showing moderate left main lesions.   This reality should be looked into, since operating or intervening moderate left main lesions on<a href="https://solaci.org/en/2021/06/25/ivus-vs-ifr-for-left-main-decision-making/" title="Read more" >...</a>

EuroPCR 2021 | EBC MAIN: Provisional Stenting vs. Systematic Dual Stenting in Left Main Coronary Artery

Treating the left main coronary artery with provisional stenting was non-inferior to systematic dual stenting in the EBC MAIN trial, presented at EuroPCR 2021 and simultaneously published in the European Heart Journal. The composite primary endpoint of death, infarction, and target-lesion revascularization was 14.7% for provisional stenting vs. 17.7% for systematic dual stenting (hazard ratio:<a href="https://solaci.org/en/2021/05/29/europcr-2021-ebc-main-provisional-stenting-vs-systematic-dual-stenting-in-left-main-coronary-artery/" title="Read more" >...</a>

Webinar SOLACI 03-03 | Angioplastia de Tronco de Coronaria Izquierda y Bifurcaciones: Registro LATAM Bif

Watch again our Webinar on Left Main PCI and Bifurcations: LATAM Bif Registry

Watch again our Webinar on “Left Main PCI and Bifurcations: LATAM Bif Registry” on our Youtube account. The event was held on March 3rd, 2021, and had the participation of almost 700 people and the support of ABBOTT, Boston Scientific, Medtronic and Terumo. Webinar Contents 00:02 | Introduction – Dr. José Mangione (BRA). 04:58 |<a href="https://solaci.org/en/2021/03/04/watch-again-our-webinar-on-left-main-pci-and-bifurcations-latam-bif-registry/" title="Read more" >...</a>

03/03 | SOLACI Webinar – Left Main PCI and Bifurcations: LATAM Bif Registry

We invite you to participate in the first free SOLACI virtual event of 2021. It is carried out with the support of Abbott, Boston Scientific, Medtronic and Terumo Interventional Systems and will have the participation of prestigious hemodynamicists from Latin America and the world. The title of the event is: “Left Main PCI and Bifurcations:<a href="https://solaci.org/en/2021/03/01/03-03-solaci-webinar-left-main-pci-and-bifurcations-latam-bif-registry/" title="Read more" >...</a>